Similar articles

• 'Biosimilar' drugs poised to penetrate market.

  Ledford H. Ledford H. Nature. 2010 Nov 4;468(7320):18-9. doi: 10.1038/468018a. Nature. 2010. PMID: 21048737 No abstract available.
• US biotech prepares to fight generic biologics.

  Reid B. Reid B. Nat Biotechnol. 2002 Apr;20(4):322. doi: 10.1038/nbt0402-322a. Nat Biotechnol. 2002. PMID: 11923820 No abstract available.
• Path to approval proves rocky for copycat biodrugs.

  Wadman M. Wadman M. Nature. 2005 Nov 10;438(7065):154-5. doi: 10.1038/438154a. Nature. 2005. PMID: 16281004 No abstract available.
• United States Food and Drug Administration requirements for approval of generic drug products.

  Meyer MC. Meyer MC. J Clin Psychiatry. 2001;62 Suppl 5:4-9; discussion 23-4. J Clin Psychiatry. 2001. PMID: 11305846 Review.
• Regulatory considerations in the development of protein pharmaceuticals.

  Beatrice MG. Beatrice MG. Pharm Biotechnol. 2002;14:405-56. doi: 10.1007/978-1-4615-0549-5_8. Pharm Biotechnol. 2002. PMID: 12189729 Review. No abstract available.